Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0242379 (
lung cancer
)
71,905
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Microphthalamia-associated transcription factor (MITF) is a critical mediator in melanocyte differentiation and exerts oncogenic functions in melanoma progression. However, the role of MITF in non-small cell lung cancer (NSCLC) is still unknown. We found that
MITF
is dominantly expressed in the low-invasive
CL1
-0 lung adenocarcinoma cells and paired adjacent normal lung tissues.
MITF
expression is significantly associated with better overall survival and disease-free survival in NSCLC and serves as an independent prognostic marker. Silencing
MITF
promotes tumor cell migration, invasion and colony formation in lung adenocarcinoma cells. In xenograft mouse model,
MITF
knockdown enhances metastasis and tumorigenesis, but decreases angiogenesis in the Matrigel plug assay. Whole transcriptome profiling of the landscape of MITF regulation in lung adenocarcinoma indicates that MITF is involved in cell development, cell cycle, inflammation and WNT signaling pathways. Chromatin immunoprecipitation assays revealed that MITF targets the promoters of
FZD7
,
PTGR1
and
ANXA1
. Moreover, silencing
FZD7
reduces the invasiveness that is promoted by silencing MITF. Strikingly,
MITF
has significantly inverse correlations with the expression of its downstream genes in lung adenocarcinoma. In summary, we demonstrate the suppressive role of MITF in
lung cancer
progression, which is opposite to the canonical oncogenic function of MITF in melanoma.
...
PMID:MITF functions as a tumor suppressor in non-small cell lung cancer beyond the canonically oncogenic role. 3329 74
<< Previous
1
2
3
4
5
6
7
8
9